Endocrine Abstracts

ACE inhibitor, lizinopril, reduced cerebrovascular death, myocardial infarction and stroke. It also reduced diabetic nephropathy and increased sensitivity of insulin in people with diabetes.

The aim of this study was to determine the effects of lizinopril on cerebrovascular death, myocardial infarction, stroke, nephropathy and insulin sensitivity. Sixty patients with diabetes mellitus type 2, mean age 58.6 plus/minus 5.6 years, with similar BMI, were divided in two groups: 1-st group treated with lizinopril 5 mg and 2-nd group treated with placebo. Duration of their diabetes was over 10 years. Investigation included: previous cardiovascular disease (coronary heart disease, stroke or peripheral vascular disease), blood pressure 160/90 mmHg or more, smoker, proteinuria, cholesterol >5.2mmol/l, postprandial glycemia, fasting insulin secretion. Student's T-test and percentile was reformed in statistical analysis. After one year of treatment, in 1-st group was reduction of cardiovascular death, myocardial infarction and stroke for 20 percent than in-group with placebo. In this group blood pressure reduced from 153 plus/minus 10 / 96 plus/minus 5 mmHg to 139 plus/minus 14 / 85 plus/minus 7 mmHg (p<0.05), and proteinuria decreased (p<0.05). Postprandial glycemia was significantly lower in-group treated with lizinopril (p<0.05). Fasting insulin after treatment in 1-st group, lowered from 21.8 plus/minus 1.9 to 16.6 plus/minus 1.8 mU/l. There were no changes in body weight, serum creatinine, uric acid, potassium, cholesterol, triglicerides and serum albumin.

The results of study show that lizinopril offers prevention from cardiovascular disease and from the vascular complications of diabetes. Lizinopril have been shown to increase both skeletal muscle, blood flow and insulin sensitivity.